Diagnostic tests

Emerging Countries Seeing Huge Increases in Diabetes

The emerging countries of India, Brazil and China are seeing swift increases in the prevalence of diabetes, as financial development is met by unhealthy lifestyle choices and subsequent chronic disease, according to a new report by GBI Research.

The new report shows that these three countries have recently become major markets for diabetes care devices, as diabetes and other lifestyle diseases are set to replace infectious diseases and malnutrition as the main cause of morbidity and mortality.

A combination of genetic, social and environmental factors is driving a sudden increase in diabetes within emerging countries. Over the past two decades, economic advancement in these countries has caused changes in the living environment, resulting in altered diets and physical activity, which is increasing the prevalence of chronic, non-communicable disease like diabetes at an alarming rate.

China has the largest diabetes care devices market of all emerging countries, while Brazil came second, followed by India in third place. According to the estimates of the International Diabetes Federation (IDF), by 2030, seven of the top 10 countries with diabetes epidemics will be based in Asia, with India and China expected to be the largest diabetic prevalent countries in the world.

Increasing awareness of diabetes is resulting in the rapid growth of the diabetes care devices market in these countries, with both India and China having started educational and preventative medicine programs. GBI Research also expects market growth to be encouraged by the substantial increase in personal disposable income and increasing affordability of healthcare.

The diabetes care devices market in China, India, and Brazil is forecast to reach $1.7 billion by 2017, following growth at a Compound Annual Growth Rate (CAGR) of 6%. The diabetes care devices market in China was valued at $700.7m in 2010 and is expected to exceed $1 billion by 2017, while the Brazilian market is valued at $294.7m in 2010, and is expected to reach $445.6m by 2017. The diabetes care devices market in India was valued at $137m in 2010, and is estimated to reach $265m by 2017.

Randox provide all the tests needed to assess Diabetes:

  • Fructosamine
  • Glucose
  • HbA1c

And for monitoring the complications of Diabetes

  • Albumin
  • Creatinine
  • Cystatin C
  • Ketones
  • Microalbumin
  • Non-esterified fatty acid (NEFA)
  • Total protein

To ensure you get a comprehensive patient assessment and enable correct treatment and monitoring, choose the Randox Diabetes Profile.



Leave a Reply

Your email address will not be published. Required fields are marked *